uniQure Secures $259M in Share Sale to Fund Gene Therapy Programs
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure completed a share sale, raising approximately $259 million gross by selling 5.69 million shares at $45.50. This substantial capital infusion follows the recent pricing of the offering and shareholder approval for increased share capital. The funds are critical for advancing the company's AMT-130 gene therapy programs, including commercialization efforts and R&D. This financing provides a significant runway, enabling the company to pursue its regulatory and development goals, especially after the FDA agreed to accept 3-year Phase I/II data for AMT-130. A Biologic License Application (BLA) submission for AMT-130 is planned for Q3 2026. Mizuho also raised its price target to $68.
At the time of this announcement, QURE was trading at $49.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.